ArticleThe Indian journal of medical research2026
Molecular subtyping and POLE mutation spectrum in endometrial carcinoma.
Article in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Endometrial carcinoma is the most common gynaecological malignancy and an emerging global health concern with limited molecular data from Indian cohorts. Our study investigated the molecular subtypes and POLE gene mutation spectrum in the South Indian cohort. Methods Molecular subtyping was carried out using ProMisE classification, categorising patients into four molecular subgroups. This involved immunohistochemistry for mismatch repair proteins, p53abn, and Sanger sequencing for POLE mutations. POLE variants were further classified, and the pathogenicity was evaluated using in silico tools. Results Histopathology presented endometrioid carcinoma in 84.9% (n= 45) cases in our study. Molecular classification revealed POLE ultra-mutated (3.8%, n=2), MMR-deficient (18.9%, n=10), p53-abnormal (17.0%, n=9), and NSMP (37.7%, n=20) subgroups. POLE gene sequencing identified 11 exonuclease domain variants, including the recurrent endometrial carcinoma hotspot V411L (3.8% ,n=2) and ten non-hotspot variants such as T323I, T457M, T466I, V460M, L306P, P441S, A465V, T290I, E321K, and T278A (22.6%, n=12). Among these, six variants T466I, V460M, L306P, P441S, T290I, and E321K were unique in our cohort, and V460M, P441S, T290I, and E321K were predicted to have oncogenic potential. Clinically, p53abn tumours showed an aggressive phenotype with higher rates of advanced-stage disease and chemotherapy use (55.6%, n=5) compared with POLE-mutated (n=0), Mismatch repair-deficient (MMRd) (37.5%, n=3), and no specific molecular profile (NSMP) tumours (10.0%, n=2). Interpretation and conclusions This study demonstrates that integrating molecular profiling with histopathology to develop clinically applicable assays strengthens endometrial carcinoma classification and improves routine prognostic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.